InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,173.20
(
1.85%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.78
(
0.18%
)
Bitcoin
59,080.08
(
-0.07%
)
Post# of 251690
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 212786

Tuesday, 09/12/2017 9:30:34 AM

Tuesday, September 12, 2017 9:30:34 AM

Post# of 251690
ICPT –16% on Ocaliva safety warning:

https://t.co/fFsTjIEa2w

Liver injury, liver decompensation, liver failure, and death have been reported in patients with moderate to severe hepatic impairment when OCALIVA was dosed more frequently than recommended in labeling for such patients. In addition, serious liver adverse events have been reported in patients initiating therapy without cirrhosis or with mild liver impairment. Liver- related adverse events have occurred both early in treatment and after months of treatment.

It shouldn't be a surprise that Ocaliva has bad side effects—no optimization was ever performed on this purportedly "natural" compound.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up